Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
October 19 2020 - 4:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of the
Securities
Exchange Act of 1934
For
the month of October 2020
Commission
File Number: 001-36581
Vascular
Biogenics Ltd.
(Translation
of registrant’s name into English)
8
HaSatat St.,
Modi’in,
Israel
7178106
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F [X] Form 40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes
[ ] No [X]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
[ ] No [X]
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
EXPLANATORY
NOTE
On
October 19, 2020, Vascular Biogenics Ltd. (the “Company”) announced an extraordinary general meeting of shareholders
(the “Meeting”) and made available to its shareholders certain other materials in connection with such meeting.
Furnished
herewith as Exhibits 99.1 and 99.2, respectively, are the following documents relating to the Meeting:
1.
|
Notice of the Extraordinary General Meeting of Shareholders to be held on November 24, 2020.
|
|
|
2.
|
Proxy Statement and Proxy Card for use in connection with the Meeting.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
VASCULAR
BIOGENICS LTD.
|
|
|
|
Date:
October 19, 2020
|
By:
|
/s/
Dror Harats
|
|
Name:
|
Dror
Harats
|
|
Title:
|
Chief
Executive Officer
|
EXHIBIT
INDEX
The
following exhibits are furnished as part of this Form 6-K:
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Sep 2023 to Sep 2024